Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25190282 | 1.00 | KDM1A (0.36) | KDM1AMAOAMAOBDPP4 | |
| SCHEMBL25189721 | 1.00 | KDM1A (0.36) | KDM1AMAOAMAOBDPP4 | |
| SCHEMBL530001 | 1.00 | KDM1A (0.36) | KDM1AMAOAMAOBDPP4 | |
| Hydrochloric Acid SCHEMBL30504893 | 0.98 | KDM1A (0.35) | KDM1AMAOAMAOBDPP4 | |
| SCHEMBL19021212 | 0.86 | IRAK4 (0.31) | — | |
| SCHEMBL18987765 | 0.86 | IRAK4 (0.31) | — | |
| SCHEMBL18987767 | 0.86 | IRAK4 (0.31) | — | |
| SCHEMBL8487578 | 0.83 | KDM1A (0.33) | KDM1AMAOAMAOB | |
| SCHEMBL1811563 | 0.80 | — | — | |
| SCHEMBL1813325 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4430034-A1 | N-(4-AMINOCYCLOHEXYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AS CD38 INHIBITORS | Cerevance, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023159322-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023084206-A1 | N-(4-AMINOCYCLOHEXYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AS CD38 INHIBITORS | CEREVANCE LTD (GB) | 2023-05-19 | — | — | WO | disclosed |
| EP-2597955-B1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| CN-103153063-A | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE INC | 2013-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NADK, NEK1 | KDM1A 837/4885MAOA 902/4885MAOB 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.